Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Acceptability of Localized Cancer Risk Reduction Interventions Among Individuals at Average or High Risk for Cancer.

Samimi G, Heckman-Stoddard BM, Kay SS, Bloodgood B, Coa KI, Robinson JL, Tennant B, Ford LG, Szabo E, Minasian L.

Cancer Prev Res (Phila). 2019 Apr;12(4):271-282. doi: 10.1158/1940-6207.CAPR-18-0435. Epub 2019 Mar 1.

PMID:
30824471
2.

A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.

Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, Sepeda V, O'Kane H, Krasne M, Williams S, Morris PG, Heckman-Stoddard BM, Dunn BK, Hudis CA, Brown PH, Dannenberg AJ.

Cancer Prev Res (Phila). 2018 Apr;11(4):203-214. doi: 10.1158/1940-6207.CAPR-17-0354. Epub 2018 Feb 16.

3.

Repurposing metformin for the prevention of cancer and cancer recurrence.

Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG.

Diabetologia. 2017 Sep;60(9):1639-1647. doi: 10.1007/s00125-017-4372-6. Epub 2017 Aug 3. Review.

4.

Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.

Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM; Diabetes Prevention Program Research Group.

Diabetologia. 2017 Sep;60(9):1601-1611. doi: 10.1007/s00125-017-4361-9. Epub 2017 Aug 2. Review.

5.

Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.

Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N.

Breast Cancer Res Treat. 2016 Jul;158(1):67-77. doi: 10.1007/s10549-016-3849-1. Epub 2016 Jun 10.

6.

Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications.

Mullooly M, Pfeiffer RM, Nyante SJ, Heckman-Stoddard BM, Perloff M, Jatoi I, Brinton LA, Aiello Bowles EJ, Hoover RN, Glass A, Berrington de Gonzalez A, Sherman ME, Gierach GL.

J Clin Oncol. 2016 Jun 20;34(18):2093-7. doi: 10.1200/JCO.2015.64.4492. Epub 2016 Mar 28. No abstract available.

7.

Repurposing old drugs to chemoprevention: the case of metformin.

Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, DeCensi A, Szabo E.

Semin Oncol. 2016 Feb;43(1):123-133. doi: 10.1053/j.seminoncol.2015.09.009. Epub 2015 Sep 8. Review.

8.

Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.

Gatti-Mays ME, Venzon D, Galbo CE, Singer A, Reynolds J, Makariou E, Kallakury B, Heckman-Stoddard BM, Korde L, Isaacs C, Warren R, Gallagher A, Eng-Wong J.

Cancer Prev Res (Phila). 2016 Mar;9(3):225-33. doi: 10.1158/1940-6207.CAPR-15-0269. Epub 2016 Jan 12.

9.

Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.

Fabian CJ, Kimler BF, Zalles CM, Phillips TA, Metheny T, Petroff BK, Havighurst TC, Kim K, Bailey HH, Heckman-Stoddard BM.

Cancer Prev Res (Phila). 2015 Dec;8(12):1146-55. doi: 10.1158/1940-6207.CAPR-15-0109. Epub 2015 Sep 21.

10.

A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones.

Chow HH, Garland LL, Heckman-Stoddard BM, Hsu CH, Butler VD, Cordova CA, Chew WM, Cornelison TL.

J Transl Med. 2014 Aug 14;12:223. doi: 10.1186/s12967-014-0223-0.

11.

A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.

Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan ME, Margenthaler JA, Chatterton RT Jr, Jovanovic B, Dunn BK, Heckman-Stoddard BM, Foster K, Muzzio M, Shklovskaya J, Skripkauskas S, Kulesza P, Green D, Hansen NM, Bethke KP, Jeruss JS, Bergan R, Khan SA.

Clin Cancer Res. 2014 Jul 15;20(14):3672-82. doi: 10.1158/1078-0432.CCR-13-3045.

12.

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.

Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E.

Cancer Prev Res (Phila). 2014 Sep;7(9):867-85. doi: 10.1158/1940-6207.CAPR-13-0424. Epub 2014 Jul 1. Review.

13.

Precision medicine clinical trials: defining new treatment strategies.

Heckman-Stoddard BM, Smith JJ.

Semin Oncol Nurs. 2014 May;30(2):109-16. doi: 10.1016/j.soncn.2014.03.004. Review.

14.

Health disparities around the world: perspectives from the 2012 Principles and Practice of Cancer Prevention and Control course at the National Cancer Institute.

Chawla N, Kepka DL, Heckman-Stoddard BM, Horne HN, Felix AS, Luhn P, Pelser C, Barkley J, Faupel-Badger JM.

J Oncol Pract. 2013 Nov;9(6):e284-9. doi: 10.1200/JOP.2013.001129. Epub 2013 Oct 1.

15.

Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.

Lazzeroni M, Serrano D, Dunn BK, Heckman-Stoddard BM, Lee O, Khan S, Decensi A.

Breast Cancer Res. 2012 Oct 29;14(5):214. doi: 10.1186/bcr3233. Review.

16.

Impact of tobacco control interventions on smoking initiation, cessation, and prevalence: a systematic review.

Wilson LM, Avila Tang E, Chander G, Hutton HE, Odelola OA, Elf JL, Heckman-Stoddard BM, Bass EB, Little EA, Haberl EB, Apelberg BJ.

J Environ Public Health. 2012;2012:961724. doi: 10.1155/2012/961724. Epub 2012 Jun 7. Review.

17.

Enhancing a cancer prevention and control curriculum through interactive group discussions.

Forsythe LP, Gadalla SM, Hamilton JG, Heckman-Stoddard BM, Kent EE, Lai GY, Lin SW, Luhn P, Faupel-Badger JM.

J Cancer Educ. 2012 Jun;27(3):428-35. doi: 10.1007/s13187-012-0376-6.

18.

Oncology biomarkers: discovery, validation, and clinical use.

Heckman-Stoddard BM.

Semin Oncol Nurs. 2012 May;28(2):93-8. doi: 10.1016/j.soncn.2012.03.003. Review.

PMID:
22542316
19.

P190A RhoGAP is required for mammary gland development.

Heckman-Stoddard BM, Vargo-Gogola T, Herrick MP, Visbal AP, Lewis MT, Settleman J, Rosen JM.

Dev Biol. 2011 Dec 1;360(1):1-10. doi: 10.1016/j.ydbio.2011.09.006. Epub 2011 Sep 16.

20.

P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis.

McHenry PR, Sears JC, Herrick MP, Chang P, Heckman-Stoddard BM, Rybarczyk M, Chodosh LA, Gunther EJ, Hilsenbeck SG, Rosen JM, Vargo-Gogola T.

Breast Cancer Res. 2010;12(5):R73. doi: 10.1186/bcr2643. Epub 2010 Sep 22.

21.

Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression.

Heckman-Stoddard BM, Vargo-Gogola T, McHenry PR, Jiang V, Herrick MP, Hilsenbeck SG, Settleman J, Rosen JM.

Breast Cancer Res. 2009;11(4):R61. doi: 10.1186/bcr2352. Epub 2009 Aug 24.

Supplemental Content

Loading ...
Support Center